Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

CRCC LLC

Neither a doctor nor a teaching hospital

Research payments

$643,086

148 payments

Through program year 2025, CRCC LLC is reported as receiving $643,086 in research payments, across 148 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,058 3
2024 Research $26,110 4
2023 Research $43,384 5
2022 Research $41,843 9
2021 Research $160,745 14
2020 Research $130,569 37
2019 Research $236,377 76

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $287,823 18 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $119,028 12 payments
  3. AbbVie, Inc. $59,617 22 payments
  4. Regeneron Pharmaceuticals, Inc. $53,326 33 payments
  5. Aclaris Therapeutics, Inc. $49,308 10 payments
  6. Merz North America, Inc. $28,464 15 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $22,113 6 payments
  8. Boehringer Ingelheim International GmbH $9,249 6 payments
  9. LEO Pharma AS $7,500 4 payments
  10. Boehringer Ingelheim Pharma GmbH & Co.KG $4,391 21 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $81,660 4 payments
  2. BI 730357 PoCC and dose ranging in Psoriasis $74,805 6 payments
  3. A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis $73,264 2 payments
  4. A Phase 2 Study of Regn2810, A Fully Human Monoclonal Antibody to Programmed Death-1, in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, Or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy $49,593 30 payments
  5. A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice A Week in Subjects With Common Warts $49,308 10 payments
  6. M16-045 $45,861 18 payments
  7. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Patients With Moderate-To-Severe Atopic Dermatitis $44,376 3 payments
  8. BI 730357 Psoriasis Long Term Extension $44,223 6 payments
  9. An Open-Label 24-Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis and Skin of Color $26,381 2 payments
  10. A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment $22,113 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record